RESEARCH DIGEST · SAFETY LENS
Ipamorelin: one failed human trial, a two-hour half-life, and a long-term safety line that is still blank.
The tolerability record read first — reported side effects, the pharmacokinetics, and the open questions, with every quantitative claim pinned to the study that measured it.
Start here
Ipamorelin is a lab-made peptide (a short chain of five building blocks called amino acids) that tells the pituitary gland — a pea-sized gland under the brain — to release a pulse of growth hormone. Its claim to fame is being clean: it raises growth hormone without raising the stress hormone cortisol [1]. People in research-use communities try it for deeper sleep, faster recovery, and a slowly leaner body. Here is the honest state of the evidence: the one real human trial, in surgery patients, did not work — it missed its goal [3]. In people, the drug leaves the blood fast, with a half-life of about two hours [2]. And no long-term human safety study exists in anyone. This site reads that record from the safety side first. What people report — including the downsides — is on the effects page, and the time-in-body numbers are on the half-life page. Nothing here is a dose, a prescription, or medical advice.
The safety record in one screen
Start with the numbers that matter for tolerability. Ipamorelin has exactly one published human efficacy trial, and it failed. In 114 adults recovering from bowel surgery, 0.03 mg/kg given by vein twice daily moved the median time to a first tolerated meal to 25.3 hours, versus 32.6 hours on placebo — a difference that was not statistically significant (p=0.15) [3]. The flip side: in that short perioperative window, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm, so the drug did not add a safety signal over surgery itself [3].
In healthy volunteers, ipamorelin clears quickly — a terminal half-life of roughly 2 hours by vein, with the growth-hormone response arriving as a single pulse about 40 minutes after dosing [2]. That short residence is the reproducible PK fact this site keeps returning to.
What is missing is the long view. No Phase 3 trial has been run, and no long-term human safety database exists [3]. A 28-day study of a different growth-hormone-secretagogue-receptor agonist (same receptor class, not ipamorelin itself) found dose-dependent heart-muscle damage in rats [6] — a class-level signal that is the reason "we don't know the chronic risk" is the correct sentence here, not a reassurance.
What ipamorelin is, in plain terms
Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; also coded NNC 26-0161) is a synthetic pentapeptide — five amino acids, wholly man-made, not a hormone your body produces. It works by switching on the ghrelin receptor (GHS-R1a), the same receptor the natural "hunger hormone" ghrelin uses, on the growth-hormone-producing cells of the pituitary [1]. Flipping that switch triggers a discrete pulse of growth hormone (GH).
Its defining trait is selectivity. In its founding 1998 characterization, ipamorelin released GH as potently as the older peptide GHRP-6 (swine ED50 2.3 nmol/kg vs 3.9 nmol/kg) yet did not raise ACTH or cortisol above the level seen with GHRH — even at doses more than 200-fold above its GH-releasing threshold [1]. That cortisol-and-prolactin-sparing profile is what separated it from earlier growth-hormone-releasing peptides.
A naming note that matters for safety: this site is about pure ipamorelin, not the popular CJC-1295 + ipamorelin combination. The two are different molecules studied differently; where the combination has data, this site labels it as such on the Ipamorelin research page.
"Prescribed" is the wrong word — here is why that matters
The domain says "prescribed," and the honest correction belongs up front: ipamorelin is not a prescribable, approved drug. It has never been approved by the FDA, the EMA, or any regulatory authority, for any indication [3]. The only indication that ever reached Phase 2 — postoperative ileus — failed its primary endpoint, and no further clinical development followed [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening compounding-pharmacy access rather than opening it.
So "prescribed ipamorelin" describes a thing that, strictly, does not exist as an approved prescription product. What exists is research-grade material and a literature — most of it preclinical, some of it human PK, one failed human trial — and that literature is what this site documents. Recent narrative reviews reach the same conclusion: a 2026 gerontology review groups ipamorelin with non-approved peptides lacking long-term safety data [17], and a 2026 orthopaedic review calls for rigorous clinical evaluation before any adoption [16].
How to read this site
The pages are ordered the way a careful reader would want them. Ipamorelin effects leads with what people actually report — benefits and downsides, clearly labeled as anecdote — then the cited safety cautions. Ipamorelin research covers the mechanism, the human PK trial, the failed efficacy trial, and the CJC-1295 / sermorelin / tesamorelin comparisons. The dosing page describes only what was administered to which species at which dose — never a human recommendation. Two focused pages answer the questions people search most from the safety angle: does ipamorelin cause water retention and how long does ipamorelin stay in your system. Every figure on every page traces back to a numbered source in the Ipamorelin references.